Malignant neoplasm

Disease2 papers

Humans2

Trial sponsors

Merck & Co.
Company2 trialsPhase 2450 people
Alliance for Clinical Trials in Oncology
2 trialsPhase 3729 people
Academic and Community Cancer Research United
1 trialPhase 3300 people
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2 trialsPhase 239 people
M.D. Anderson Cancer Center
1 trialPhase 2135 people
Fred Hutchinson Cancer Center
1 trialPhase 283 people
Mayo Clinic
1 trialPhase 19 people

Latest

11

Journal of Clinical PathologyHumans2 Oct

Incidental detection of JAK2 V617F mutations in next-generation sequencing analysis of solid tumours: a guide to further workup

Frontiers in PharmacologyReview18 Sep

Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Science China Life SciencesIn silico17 Sep

Burden of cancer in China from 1990 to 2023 and projections to 2050

Nutrition and HealthHumans8 Sep

Nutritional characteristics of the 1975-type Japanese diet and its potential relevance to healthy aging and longevity

Cancer MedicineHumans7 Sep

Cancer Risk Among Young Adults With Clinically Diagnosed Fatty Liver Disease: A Nationwide Cohort Study in South Korea

Preprints.orgHumansPreprint4 Sep

Temporal Trends in Cancer Mortality in Serbia, 2000–2021: A Nationwide Population Study

Epidemiology and HealthHumans3 Sep

Mortality and causes of death in the Korean Genome and Epidemiology Study (KoGES), 2001-2023

Evolutionary ApplicationsHumans3 Sep

A Comparative Analysis of Aging Across Causes of Death

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Clinical outcomes associated with utilization of Glucagon-like Peptide-1 Receptor Agonists in heart failure patients in the United States

AHA Scientific Sessions 2025 AbstractReview3 Nov

Cardiovascular Outcomes of Oral Semaglutide in High Risk Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis